
Please try another search
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a collaboration agreement with Monash University and National Cancer Institute IND. It also has a cooperative research and development agreement with the U.S. Army, Island in preparation for its Phase 2a/b clinical study for ISLA-101. Island Pharmaceuticals Limited was founded in 2017 and is based in Camberwell, Australia.
Name | Age | Since | Title |
---|---|---|---|
Jason Alan Carroll | - | 2025 | Director |
David Charles Foster | - | 2020 | MD, CEO, President & Executive Director |
Amy K. Patick | - | 2022 | Member of Scientific Advisory Board |
Stephen J. Thomas | - | - | Member of Scientific Advisory Board |
Christopher Leo Ntoumenopoulos | 42 | 2024 | Independent Non-Executive Director |
Jason Alan Carroll | - | 2025 | Non-Executive Chair |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review